&

Would like to invite you to join us on

Monday December 7th 6:00PM - 9:00 PM

Biotech Conference & Business Mixer

"A Window into Lyon Life Science Companies"

''Lyonbiopole'', the French center of excellence in vaccines and diagnostics, is coming to the San Diego Area. Meet French life sciences executives from Lyon, the capital of immunology and bioproduction in France and Europe and learn about their innovative approaches to immunomonitoring, vaccine therapy and biomanufacturing. Imaxio is a biopharmaceutical company specializing in oncology and infectious diseases, for which the company develops and commercializes diagnostic and therapeutic products. ImmunID offers innovative immunomonitoring & diagnostic solutions to characterize immune dysfunction and analyzes the impact of immunotherapy on Immune Repertoire. PX Therapeutics provides integrated bio therapeutics and recombinant vaccines development and manufacturing contract services.  Join us for an evening of unique insights into 3 French life sciences companies. 

Program:

- 6:00 - 6:30 PM - Guest registration

- 6:30 - 6:35  - Welcoming by Stephane Richard, Founder of French BIO Beach

- 6:35 - 7:20 - Integrated Solutions for immunotherapy Development: Case Studies from Lyon

Moderator

Xavier Frapaise, CSO, Optimer Pharmaceuticals

Panel

FrançoisMiceli, CEO, Imaxio (Vaccinotherapy)

Nicolas Pasqual, CEO and co-founder, ImmunID Technologies (Immunomonitoring)

Christelle Dagoneau, Business Development Director, PX Therapeutics  (Biomanufacturing)

-7:30 - 9:00 - Concluding Remarks and Cocktail opening

If you wish to attend to this event, please don’t forget to register online.

This event is hosted by French BIO Beach and highly supported by the LyonBioPole, the ADERLY and the Invest in France Agency. 

Xavier Frapaise, CSO, Optimer Pharmaceuticals

Academic position : Loyola University Medical Center/ Thrombosis Research Center, Maywood IL
Currently Sr. VP and Chief Scientific Officer at Optimer Pharmaceuticals, San Diego, a company in late stage development of 2 new anti-bacterials
31 yrs of drug development experience in Europe and USA, at “big Pharma” (Sanofi, Bayer, Abbott) and San Diego-based biotech companies (Ocera, Asphelia).

      François Miceli, CEO, Imaxio

Imaxio is a biopharmaceutical company specializing in the fields of oncology and infectious diseases, for which the company develops and commercializes diagnostic and therapeutic products. As for example, company markets throughout France a vaccine against leptospirosis. In collaboration with the University of Oxford, through a Grand Challenges in Global Health grant to the Jenner Institute, novel viral vector vaccines against neglected diseases are being developed which incorporate Imaxio's proprietary aXent^TM adjuvant. (Industrial partnership agreements have also been signed for the adjuvant).

 Nicolas Pasqual, CEO and co-founder, ImmunID Technologies

Thanks to its original concept of "Immune Weather Forecast" ImmunID offers innovative immunomonitoring & diagnostic solutions to characterize immune dysfunction and analyse the impact of immunotherapy on Immune Repertoire. ImmunID solutions are used from research to clinical validation to measure efficacy and toxicity risk of molecules such as Monoclonal antibodies (anti-CD20...), Interleukins (IL2, IL7...), or vaccines (prophylactic or therapeutic). ImmunID solutions are used to diagnose certain pathologies such as Lymphoma and Leukemia, and to monitor immunodeficiency and follow up disease progression and immunomodulators efficacy. Pathologies mainly concerned are blood cancers, infectious diseases, cancers, autoimmune diseases.
 

         Christelle Dagoneau, Business Development Director, PX Therapeutics

The company provides integrated bio therapeutics and recombinant vaccines development and manufacturing contract services. They are organized around three integrated service platforms : recombinant protein R&D, monoclonal antibody development and cGMP manufacturing. ). They gained substantial experience in the production of challenging proteins and developed trusted relationships with more than 140 pharmaceutical, biotech and academic partners worldwide, as for example : Merial, Sanofi Pasteur, Biomérieux, BD, Tibotec, GSK, Pfizer, Galderma, Stallergenes, etc.

French BioBeach Partners & Sponsors: